Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Stressing Statistical Outcomes Over Standardization In Imaging Trials

Executive Summary

FDA is emphasizing statistical outcomes over protocol standardization when assessing imaging studies, according to Division of Medical Imaging Drug Products Director George Mills

You may also be interested in...



President’s Budget Paves The Critical Path With $6 Mil. Request

FDA requests $6 mil. and six FTEs for its Critical Path initiative in fiscal 2007, marking the first time funding has been proposed for the program

President’s Budget Paves The Critical Path With $6 Mil. Request

FDA requests $6 mil. and six FTEs for its Critical Path initiative in fiscal 2007, marking the first time funding has been proposed for the program

Exploratory INDs Will Better Serve Large Companies, PDL Exec Says

Exploratory investigational new drug applications will provide a greater benefit to large pharma and biotech companies, Protein Design Labs CEO Mark McDade said at the Biotechnology Industry Organization Windhover conference in Washington, D.C. April 26

Topics

UsernamePublicRestriction

Register

ID020288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel